Advancing Whole Genome Amplification

Courtesy of Molecular Staging  UNRAVELING MDA: Molecular Staging's MDA technology relies on a highly processive, strand-displacing DNA polymerase. As high-throughput genomics and its postgenomics successor, proteomics, are the technologies of choice for rapid screening of new pharmaceuticals, a company that establishes itself as a technology leader in both fields could be ahead of the pack: New Haven, Conn.-based Molecular Staging (MSI). In November 2002, MSI announced in rapid successi

Myrna Watanabe
Jan 12, 2003
Courtesy of Molecular Staging
 UNRAVELING MDA: Molecular Staging's MDA technology relies on a highly processive, strand-displacing DNA polymerase.

As high-throughput genomics and its postgenomics successor, proteomics, are the technologies of choice for rapid screening of new pharmaceuticals, a company that establishes itself as a technology leader in both fields could be ahead of the pack: New Haven, Conn.-based Molecular Staging (MSI).

In November 2002, MSI announced in rapid succession that 1) it received a Small Business Innovation Research (SBIR) grant from the US Department of Energy's Genomes to Life program to develop MSI's multiple displacement amplification (MDA) technology for DNA amplification and identification of microbes; 2) its REPLI-g™ Whole Genome Amplification kits are now available; and 3) it received an SBIR award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, to develop a chip that detects osteoarthritis protein biomarkers.

REPLI-g is a line of kits that make...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?